TABLE 7Continued Trial Phase Control arm Country Experimental treatment regimen(s) Experimental treatment duration, months Notes ClinicalTrials.gov identifier endTB 3 Yes Multicountry Bedaquiline, moxifloxacin, linezolid, and pyrazinamide or bedaquiline, clofazimine, levofloxacin, linezolid, and pyrazinamide or bedaquiline, delamanid, levofloxacin, linezolid, and pyrazinamide or delamanid, clofazimine, levofloxacin, linezolid, and pyrazinamide or delamanid, clofazimine, moxifloxacin, and pyrazinamide 9 Trial implementing Bayesian adaptive randomisation NCT02754765 GRACE-TB NS Yes China Individualised regimens NS Individualised regimen guided by rapid molecular tests NCT03604848 InDEX 4 Yes South Africa Individualised regimens NS Gene-derived individualised regimen NCT03237182 PROSPECT 4 No China Clofazimine, cycloserine, levofloxacin, linezolid, and prothionamide or bedaquiline, clofazimine, cycloserine, levofloxacin, and linezolid 6 (first regimen), 9 (second regimen) NCT05306223 TB-TRUST 3 Yes China Levofloxacin, linezolid, cycloserine, and pyrazinamide (or clofazimine if resistant to pyrazinamide) 69 NCT03867136 Rifampicin-resistant, fluoroquinolone-resistant tuberculosis endTB-Q 3 Yes Multicountry Bedaquiline, clofazimine, delamanid, and linezolid 69 Strategy trial duration adapted to extent of disease and treatment response. NCT03896685 mBPaL 3 No India Bedaquiline, pretomanid, and linezolid at different dosages 6 NCT05040126 NS: not stated. Reproduced and modified from [8] and [82] with permission. Data from [91]. https://doi.org/10.1183/2312508X.10024622 133 TREATMENT OF DS-TB AND DR-TB |C. LANGE ET AL.